PsiOxus Therapeutics, Ltd. (PsiOxus) has announced top line positive data from a Phase II clinical trial of MT-102 in cancer-related cachexia. The primary endpoint has been met in the recently completed Phase II multinational, randomized, double blind, placebo controlled clinical trial (also known as the ACT1 study), which was undertaken to examine the effect of MT-102 in patients with cachexia due to underlying stage III and IV colon or lung cancer.
The data show that patients treated with MT-102 over a 16 week period have greater weight gain when compared to placebo treated patients, and at the highest dose of MT-102 (10mg twice daily) the difference is statistically significant. The clinical study has thus demonstrated MT-102’s ability to halt the cycle of weight loss, weakness and fatigue of cachectic late stage cancer patients.
Click here to read the full story
Posted on Wednesday 13th November 2013